No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - American healthcare and medical device giant Johnson & Johnson matched analysts' estimates with its fourth-quarter results, as earnings jumped on the back of improved sales of cancer and autoimmune drugs.
The company also delivered better-than-expected guidance for the current financial year, but shares were lower in pre-market trading.
Sales totalled $24.6bn over the final three months of 2025, up 9.1% over the year before, with Innovative Medicine sales - which account for 64% of group sales - rising 10% to $15.8bn.
Innovative Medicine results were helped by a 24.8% surge in oncology sales to $6.8bn, with a standout performance from its best-selling multiple myeloma treatment Darzalex (+26.6% at $3.9bn).
That helped to mitigate the impact of a 8.9% decline in immonology sales to $3.9bn after the division's flagship skin and gut treatment Stelara lost patent protection last year, with sales dropping 47.7% to $1.23bn. That was slightly offset by a strong performance from autoimmune treatment Tremfya which saw a 67.6% jump in sales to $1.59bn.
Net earnings increased 49.1% to $5.12bn, while earnings per share surged to $2.10 from $1.41 previously. On an adjusted basis, EPS jumped 20.6% to $2.46, in line with analysts' forecasts.
"2025 was a catapult year for Johnson & Johnson, fuelled by the strongest portfolio and pipeline in our history," said chair and chief executive Joaquin Duato. He said 2025 kickstarted a "new era of accelerated growth", driven by medical innovation across the business.
Sales for the whole of 2025 rose 6.0% to $94.2bn, while adjusted net earnings increased 8.1% to $26.2bn, with adjusted EPS rising to $10.79 from $9.98.
Looking ahead, the company guided to sales rising 6.7% to $100.5bn at the mid-point of the guidance range, while adjusted EPS is expected to jump 6.9% to $11.53. Both targets were ahead of market forecasts.
JNJ futures were down 3.3% at $211.07 by 1321 GMT.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.